ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Organogenesis Holdings Inc

Organogenesis Holdings Inc (ORGO)

2,395
-0,025
( -1,03% )
Aktualisiert: 16:07:45

Organogenesis Holdings Inc (ORGO) Aktie

Professionelle Tools für Privatanleger.

Premium

Wichtige Statistiken und Details

Current Price
2,395
( -1,03% )
Gebot
2,39
Fragen
2,40
Volumen
62.318
2,39 Tagesbereich 2,445
2,04 52-Wochen-Bereich 7,0771
Marktkapitalisierung
Handelsende
2,42
Handelsbeginn
2,41
Letzte Trade
100
@
2.395
Letzter Handelszeitpunkt
16:07:50
Finanzvolumen
US$ 150.317
VWAP
2,4121
Durchschnittliches Volumen (3 Mio.)
US$ 1.518.238
Ausgegebene Aktien
128.674.548
Dividendenrendite (LTM)
Kurs-Gewinn-Verhältnis
-22,16
Gewinn pro Aktie (EPS)
-0,12
Erlöse (LTM)
514,7M
Nettogewinn (LTM)
2,72M

Über Organogenesis Holdings Inc

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion p... Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, VIA Matrix, and SimpliMax are placental tissue grafts used to treat chronic and acute wounds that can be stored at room temperature. The company also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; and TransCyte, a bioengineered tissue scaffold that promotes burn healing. In addition, it develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products. The company serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies. Organogenesis Holdings Inc. is headquartered in Canton, Massachusetts. Mehr anzeigen

Sektor
Healthcare
Branche
Pharmaceuticals
Hauptsitz
Canton, United States
Gegründet
-
Organogenesis Holdings Inc is listed in the Healthcare sector of the NASDAQ with ticker ORGO. The last closing price for Organogenesis was US$2,42. Over the last year, Organogenesis shares have traded in a share price range of US$ 2,04 to US$ 7,0771.

Organogenesis currently has 128.674.548 shares in issue. The market capitalisation of Organogenesis is US$308,18 million. Organogenesis has a price to earnings ratio (PE ratio) of -22.16.

ORGO Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-0.165-6.44531252.562.562.189011202.37180665CS
40.0351.483050847462.362.7852.1812802172.51633519CS
12-0.245-9.28030303032.642.7852.0415252682.41786565CS
26-2.395-504.795.9052.0412246183.23023009CS
52-0.985-29.14201183433.387.07712.0412186254.04633672CS
156-1.825-43.24644549764.227.07711.9610987093.8012596CS
260-13.605-85.031251617.51.79510728185.08330561CS

ORGO - Frequently Asked Questions (FAQ)

What is the current Organogenesis Holdings Inc share price?
The current share price of Organogenesis Holdings Inc is US$ 2,395
How many Organogenesis Holdings Inc shares are in issue?
Organogenesis Holdings Inc has 128.674.548 shares in issue
What is the market cap of Organogenesis Holdings Inc?
The market capitalisation of Organogenesis Holdings Inc is USD 308,18M
What is the 1 year trading range for Organogenesis Holdings Inc share price?
Organogenesis Holdings Inc has traded in the range of US$ 2,04 to US$ 7,0771 during the past year
What is the PE ratio of Organogenesis Holdings Inc?
The price to earnings ratio of Organogenesis Holdings Inc is -22,16
What is the cash to sales ratio of Organogenesis Holdings Inc?
The cash to sales ratio of Organogenesis Holdings Inc is 0,65
What is the registered address of Organogenesis Holdings Inc?
The registered address for Organogenesis Holdings Inc is 85 Dan Road, Canton, Massachusetts, 02021
What is the Organogenesis Holdings Inc website address?
The website address for Organogenesis Holdings Inc is organogenesis.com
Which industry sector does Organogenesis Holdings Inc operate in?
Organogenesis Holdings Inc operates in the Pharmaceuticals sector

ORGO Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen